2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. MAGL

MAGL

Monoacylglycerol lipase

MAGL

Related Products

PDF 0.44 MB

Monoacylglycerol lipase (MAGL) is a serine hydrolase that plays a crucial role catalysing the hydrolysis of monoglycerides into glycerol and fatty acids. MAGL links the endocannabinoid and eicosanoid systems together by degradation of the abundant endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators.

MAGL plays a critical role in lipid signalling: i) it is the major enzyme that controls the levels of 2-AG, an important lipid with various neuroprotective effects; ii) inactivation of MAGL induces an elevation in brain levels of 2-AG and a reduction of AA, a key precursor of pro-inflammatory prostaglandins, resulting in the reduction of neuroinflammation; iii) MAGL regulates the levels of free fatty acids (FFAs) in aggressive cancer cells, and this MAGL-promoted fatty acid network drives a number of pro-tumorigenic signalling pathways. MAGL is emerging as a promising drug target for various diseases.

MAGL Related Products (71):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15249
    JZL 184
    		Inhibitor 99.46%
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH.
    JZL 184
  • HY-117632
    Elcubragistat
    		Inhibitor 99.96%
    Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 14 nM.
    Elcubragistat
  • HY-119283
    CAY10499
    		Inhibitor 99.58%
    CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC50 values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities.
    CAY10499
  • HY-142161
    ABD957
    		Inhibitor 99.46%
    ABD957 is a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC50 of 0.21 μM for ABHD17B. ABD957 can block N-Ras signaling and the growth of NRAS-mutant AML cells.
    ABD957
  • HY-117474
    MJN110
    		Inhibitor 99.83%
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively. MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity.
    MJN110
  • HY-173369
    PROTAC MAGL degrader-1
    		Degrader
    PROTAC MAGL degrader-1 is an orally active PROTAC agent that simultaneously targets monoacylglycerol lipase (MAGL) and E3 ubiquitin ligase MDM2. PROTAC MAGL degrader-1 degrades MAGL and inhibits the binding of MDM2 to p53. PROTAC MAGL degrader-1 can partially penetrate the blood-brain barrier (BBB). PROTAC MAGL degrader-1 induces glioblastoma stem cells (GSCs) apoptosis. (E3 ligase ligand: HY-128837; target protein ligand + linker: HY-173370; target protein inhibitor: HY-15249).
    PROTAC MAGL degrader-1
  • HY-168459
    MAGL-IN-21
    		Inhibitor
    MAGL-IN-21 (Compound (S)-6) is a selective inhibitor for monoacylglycerol lipase (MAGL) with an IC50 of 1.59 nM.
    MAGL-IN-21
  • HY-124576
    ABD-1970
    		Inhibitor
    ABD-1970 is a selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 15 nM and 29 nM for human and mouse MAGL, respectively. ABD-1970 shows selectivity for MGLL over other members of the serine hydrolase class. ABD-1970 has the potential for the study of neurological disorders.
    ABD-1970
  • HY-114157
    DO-264
    		Inhibitor 99.96%
    DO-264 is a selective and in vivo-active inhibitor of Abhydrolase Domain Containing 12 (ABHD12), with an IC50 of 11 nM.
    DO-264
  • HY-18540
    KT109
    		Inhibitor 99.86%
    KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC50 of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC50=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages.
    KT109
  • HY-15250
    JZL195
    		Inhibitor 99.75%
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.
    JZL195
  • HY-100337
    WWL70
    		Inhibitor 99.95%
    WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 70 nM.
    WWL70
  • HY-133130
    JNJ-42226314
    		Inhibitor 99.42%
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain.
    JNJ-42226314
  • HY-120215
    KT203
    		Inhibitor 99.86%
    KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.31 nM in Neuro2A cells.
    KT203
  • HY-N0313
    Euphol
    		Inhibitor 99.01%
    Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC50=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain.
    Euphol
  • HY-116141
    7-Hydroxycoumarinyl arachidonate
    		≥98.0%
    7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer.
    7-Hydroxycoumarinyl arachidonate
  • HY-128035
    ML-211
    		Inhibitor 98.06%
    ML-211 is a carbamate-based dual inhibitor of acyl-protein thioesterase 1 (APT1)/lysophospholipase 1 (LYPLA1) (IC50=17 nM) and LYPLA2 (IC50=30 nM). ML-211 also inhibits theserine hydrolase ABHD11 with an IC50 value of 10 nM but is ≥ 50-fold selective for LYPLA in a panel of 20 additional serine hydrolases.
    ML-211
  • HY-120177
    KT182
    		Inhibitor 99.93%
    KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells.
    KT182
  • HY-108613
    JJKK 048
    		Inhibitor 99.55%
    JJKK 048 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor with IC50 values of 214 pM, 275 pM and 363 pM for human, rat, and mouse MAGL. JJKK 048 displays low cross-reactivity with other endocannabinoid targets. JJKK 048 can be used in the research of diseases such as cancer, neurodegenerative diseases, and pain.
    JJKK 048
  • HY-111538
    MAGL-IN-1
    		Inhibitor 99.78%
    MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.
    MAGL-IN-1